Record overview
Status and phase
Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Sponsor: Daiichi Sankyo
Condition: Extensive-stage Small-cell Lung Cancer
NCT05280470
Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: primary_completion_date_past_signal | long_recruitment_duration_signal
Results signal: Low Signal
Operational burden: strict_eligibility_signal
Stopped reason
Context when available
No stop reason available in the current public record.